FLEMINGTON, N.J., June 3, 2016 /PRNewswire/ -- ACT Oncology, the leading contract research organization (CRO) specializing exclusively in the field of oncology, has changed its name to Precision Oncology (precisionforoncology.com). The new name reflects the significant expansion and integration of capabilities since joining Precision for Medicine earlier this year.
Precision Oncology combines market leading oncology clinical trial design and execution with the most advanced biomarker expertise and infrastructure. These capabilities support the wide range of development; from translational research and early phase proof of concept, to pivotal studies and registration. The result is a uniquely integrated offering built to deliver an accelerated pathway to approval for oncology innovators.
"At Precision Oncology, we combine decades of experience in oncology drug development with a complete and integrated set of services to realize the potential of biomarker enabled drug development," said Patricia Devitt, president of Precision Oncology. "Biomarkers and patient stratification techniques can improve success rates and accelerate the pathway to approval," added Devitt. "But to realize these benefits, you need expertise in several new areas, from genomics and bioinformatics to liquid biopsies and companion diagnostics and with Precision for Medicine, we've added these core strengths."
"Precision Oncology unites unrivaled oncology execution capabilities with advanced bioinformatics, biospecimen management, specialty lab services, and diagnostic development under one virtual roof, with a single point of accountability," said Chad Clark, president of Precision for Medicine. "We believe combining these highly technical services is unique in the marketplace and significantly reduces the risks and costs inherent in oncology drug development."
About Precision for Medicine
Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patients more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology with a focus on genomics, immune-response assays, global specimen logistics, biomarker analytics, and companion diagnostics solutions. For more information, visit www.precisionformedicine.com.
About Precision Medicine GroupFormed in 2012, Precision Medicine Group is a specialized services company supporting next-generation approaches to drug development and commercialization. Precision Medicine Group provides an integrated infrastructure that supports pharmaceutical and life sciences companies as they develop new products in the age of precision medicine. The company is headquartered in Bethesda, Maryland, with offices throughout the United States and Europe. For more information, visit www.precisionmedicinegrp.com.
Advertisement
Precision Oncology combines market leading oncology clinical trial design and execution with the most advanced biomarker expertise and infrastructure. These capabilities support the wide range of development; from translational research and early phase proof of concept, to pivotal studies and registration. The result is a uniquely integrated offering built to deliver an accelerated pathway to approval for oncology innovators.
Advertisement
"At Precision Oncology, we combine decades of experience in oncology drug development with a complete and integrated set of services to realize the potential of biomarker enabled drug development," said Patricia Devitt, president of Precision Oncology. "Biomarkers and patient stratification techniques can improve success rates and accelerate the pathway to approval," added Devitt. "But to realize these benefits, you need expertise in several new areas, from genomics and bioinformatics to liquid biopsies and companion diagnostics and with Precision for Medicine, we've added these core strengths."
"Precision Oncology unites unrivaled oncology execution capabilities with advanced bioinformatics, biospecimen management, specialty lab services, and diagnostic development under one virtual roof, with a single point of accountability," said Chad Clark, president of Precision for Medicine. "We believe combining these highly technical services is unique in the marketplace and significantly reduces the risks and costs inherent in oncology drug development."
About Precision for Medicine
Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patients more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology with a focus on genomics, immune-response assays, global specimen logistics, biomarker analytics, and companion diagnostics solutions. For more information, visit www.precisionformedicine.com.
About Precision Medicine GroupFormed in 2012, Precision Medicine Group is a specialized services company supporting next-generation approaches to drug development and commercialization. Precision Medicine Group provides an integrated infrastructure that supports pharmaceutical and life sciences companies as they develop new products in the age of precision medicine. The company is headquartered in Bethesda, Maryland, with offices throughout the United States and Europe. For more information, visit www.precisionmedicinegrp.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/act-oncology-is-now-precision-oncology-300279542.html
SOURCE Precision for Medicine
